Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-12

Study Completion Date

2018-12-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial studies the omission of intact parathyroid hormone testing during surgery in treating patients with primary hyperparathyroidism. Omission of intact parathyroid hormone testing during parathyroid gland removal may help patients with primary hyperparathyroidism to decrease their time under anesthesia, and decrease the overall time and cost of surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Parathyroid Allotransplant for Treatment of Hypoparathyroidism

NCT06961071

Hypoparathyroidism Hypoparathyroidism Postprocedural Hypoparathyroidism Post-surgical

NOT_YET_RECRUITING PHASE1/PHASE2

Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism

NCT06859580

Primary Hyperparathyroidism

RECRUITING PHASE4

7 Day Continuous Parathyroid Hormone IV Infusion

NCT00377312

Osteoporosis Bone Diseases, Endocrine Hyperparathyroidism

COMPLETED EARLY_PHASE1

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis

NCT00172081

Osteoporosis

COMPLETED PHASE3

Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer

NCT00043069

Osteoporosis Prostate Cancer

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who meet the biochemical and radiological criteria compared to current standard of care (i.e. use of intraoperative parathyroid hormone testing).

SECONDARY OBJECTIVES:

I. Cost-analysis to determine savings of omission of intraoperative PTH testing.

OUTLINE:

Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.

After completion of study, patients are followed up at 2 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parathyroid Gland Adenoma Primary Hyperparathyroidism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supportive Care (parathyroidectomy)

Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.

Group Type EXPERIMENTAL

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Parathyroidectomy

Intervention Type PROCEDURE

Undergo parathyroidectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Parathyroidectomy

Undergo parathyroidectomy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism
* Preoperative serum calcium levels \>= 10.9 mg/dL
* Preoperative parathyroid hormone (PTH) elevated beyond normal range or inappropriately high for associated calcium level
* Patient has no history of prior neck surgery or external radiation to neck for malignant conditions
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
* Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria

* Patient has recurrent hyperparathyroidism
* 4D CT positive for multiple gland disease
* Patient has inability to tolerate 4D CT scan (for example; contrast intravenous (IV) allergy, claustrophobia, renal disease)
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Pregnant or nursing female subjects; may be determined in the preoperative evaluation
* Unwilling or unable to follow protocol requirements
* Any condition which in the investigator's opinion deems the subject an unsuitable candidate to undergo observational study (may also include preoperative testing results including electrocardiography \[EKG\], chest x-ray, or pulmonary function tests that preclude a wide excision in the operating room)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No